Exciting Funding Development Announced by bioAffinity Technologies
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a pioneering company in the field of biotechnology, has announced an exciting funding development that is set to enhance its capability in the noninvasive detection of early-stage cancer. The company has entered into a securities purchase agreement with institutional investors, underscoring its commitment to advancing technology for improved health outcomes.
Details of the Offering
In this transaction, bioAffinity Technologies is planning to sell 2,048,294 shares of common stock, priced at $1.30 each. The offering will also include a concurrent private placement of common warrants which will allow the purchase of up to 2,662,782 shares at an exercise price of $1.50 per share. This strategic move is expected to bolster the financial foundation of the company and propel it forward in its mission.
Conditions of the Offering
The much-anticipated closing of this offering is projected to occur shortly, with expectations set for late October 2024, contingent on the fulfillment of customary closing conditions. Estimated gross proceeds from the transaction are around $2,662,782, which will be instrumental in funding future developments, excluding additional revenues that may arise from the exercise of the warrants.
Role of WallachBeth Capital
WallachBeth Capital has stepped in as the sole placement agent for this significant offering. Their expertise and involvement are expected to enhance the success of this financial endeavor and ensure that the required conditions are met smoothly and efficiently.
Overview of CyPath® Lung Technology
bioAffinity Technologies is renowned for its innovative approach to early-stage cancer detection. Among its core offerings is CyPath® Lung, a revolutionary noninvasive test designed to identify malignancies in patients with potential lung cancer. This advanced solution employs proprietary flow cytometry paired with artificial intelligence to assess cell populations in sputum samples. Such advancements are turning the tide in early cancer diagnosis, potentially saving countless lives.
Performance Metrics of CyPath® Lung
The efficacy of CyPath® Lung is clearly illustrated by clinical studies revealing an impressive 92% sensitivity, 87% specificity, and an overall 88% accuracy in detecting lung cancer. The capabilities of this test are vital for patients presenting with small lung nodules, representing a significant breakthrough for noninvasive cancer diagnostics.
Company Mission and Vision
Focusing on the future, bioAffinity Technologies remains dedicated to addressing the growing necessity for effective diagnostics in the field of oncology. Their innovative portfolio aims to not only diagnose cancers at an early stage but also provide a foundation for broad-spectrum cancer treatments. Through strategic funding initiatives such as this, the company is laying the groundwork for a healthier future.
About bioAffinity Technologies, Inc.
Founded on the principles of advancing healthcare solutions, bioAffinity Technologies is committed to providing groundbreaking technology to tackle early-stage cancer detection. The company’s first product, CyPath® Lung, is marketed by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies, reinforcing its promise of innovation and quality in medical diagnostic solutions.
Frequently Asked Questions
What is the main purpose of the recent funding initiative?
The recent funding of $2.66 million is aimed at enhancing bioAffinity Technologies' capabilities in developing noninvasive tests for early-stage cancer detection.
Who is the placement agent for this offering?
WallachBeth Capital is acting as the sole placement agent for the offering, facilitating the process and ensuring a smooth transaction.
What does CyPath® Lung do?
CyPath® Lung is a noninvasive test that uses advanced technology to detect lung cancer in patients, particularly those with small nodules.
How accurate is CyPath® Lung?
Clinical studies have shown that CyPath® Lung achieves 92% sensitivity, 87% specificity, and 88% accuracy, making it highly reliable for early cancer detection.
What is the vision of bioAffinity Technologies?
bioAffinity Technologies focuses on advancing noninvasive diagnostics and broad-spectrum cancer treatments to improve early detection and patient outcomes.
